You are here: Industry Insights > msd

News List

AZ and MSD secure three bits of good news on key drug pharmafile
August 21, 2017
It was a case of three-in-one bits of good news for AstraZeneca and MSD, after the FDA boosted the newly formed Lynparza partnership with an expanded indication and new formulation approval.
Sanofi files patent infringement suit against MSD in US pharmatimes
August 10, 2017
Sanofi says that it has filed a patent infringement suit against Merck Sharp & Dohme in the United States District Court for the District of New Jersey, alleging the infringement of two patents.
Shire shifts vaccine facility from Baxalta deal to MSD pharmafile
August 09, 2017
As part of Shire’s mega-merger with Baxalta, it suddenly had a massive manufacturing network that spanned 17 sites across seven countries
MSD’s “Biosimilar” of Lantus Obtained Tentative Approval of FDA, Gan & Lee Pharmaceuticals to Snatch en-cphi.cn
August 04, 2017
MSD’s LUSDUNA Nexvue (insulin glargine injection, 100 units/ml) has recently received FDA’s tentative approval for treating Type 1 and Type 2 diabetes.
AZ attempts to clear dust of Mystic trial with $8.5 billion MSD deal pharmafile
July 28, 2017
It will be some time before the Mystic catastrophe hoo-ha dies down for AstraZeneca but it made a pre-emptive move to curtail coverage with a big announcement – the inking of an $8.5 billion deal with MSD
MSD’s Keytruda backed for bladder cancer pharmatimes
July 26, 2017
European regulators have backed expanding approval of MSD’s immunotherapy Keytruda to include the treatment of locally advanced or metastatic urothelial carcinoma, a type of bladder cancer.
MSD’s Keytruda hits rare snag, floundering in confirmatory trial pharmafile
July 26, 2017
Since the PD-1/PD-L1 immunotherapies have hit the market, they have revolutionised cancer care for many patients yet, with the science not completely understood
MSD investment confirms thriving biopharmaceutical hub europeanpharmaceuticalreview
June 12, 2017
BioPharmaChem Ireland, the Ibec group that represents business in the sector, said the announcement of MSD to invest €280 million in Ireland over the next three years bolsters the country’s status as a thriving hub for the biopharmaceutical sector.
UK CMA accuses Merck of breaking competition law with discount scheme pharmaceutical-technology
May 27, 2017
The UK Competition and Markets Authority (CMA) has accused US pharmaceutical company Merck Sharp & Dohme (MSD) of operating an anti-competitive discount scheme for its medicine Remicade.
MSD’s Keytruda closer to classical Hodgkin Lymphoma nod pharmatimes
March 28, 2017
MSD’s anti-PD-1 therapy Keytruda has taken a giant leap towards being approved in Europe for the treatment of classical Hodgkin Lymphoma (cHL).

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page